Exosomal miRNA in early-stage hepatocellular carcinoma

doi:10.12998/wjcc.v11.i3.528

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5167)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

230

WORD

HTML

2874

Tables (1-1)

636

Sum=3767

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

315

Download

1092

Sum=1407

Jan 26, 2023 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Cases. Jan 26, 2023; 11(3): 528-533
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.528

Exosomal miRNA in early-stage hepatocellular carcinoma

Zhi-Qiang Wu, Yi-Xin Zhu, Yun Jin, Yin-Chu Zhan

Zhi-Qiang Wu, Yi-Xin Zhu, Yin-Chu Zhan, Department of Surgery, The Second People's Hosptal of Quzhou, Quzhou 324000, Zhejiang Province, China

Yun Jin, Department of Surgery, The Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310009, Zhejiang Province, China

Author contributions: Wu ZQ and Zhu YX designed and reviewed the manuscript; Wu ZQ, Zhu YX, and Jin Y wrote the paper; All authors read and approved the manuscript; Wu ZQ and Zhu YX contributed equally to this work.

Supported by the Quzhou Science and Technology Guided Project Planning, No. 2019133.

Conflict-of-interest statement: We declare that we have no conﬂict of interest related to this work.

Corresponding author: Yin-Chu Zhan, MD, Director, Surgeon, Department of Surgery, The Second People's Hosptal of Quzhou, No. 338 Xin'an Avenue, Qujiang District, Quzhou 324000, Zhejiang Province, China. qzhospzyc@163.com

Received: October 28, 2022
Peer-review started: October 28, 2022
First decision: December 19, 2022
Revised: December 26, 2022
Accepted: January 5, 2023
Article in press: January 5, 2023
Published online: January 26, 2023
Processing time: 90 Days and 11.8 Hours

Abstract

The incidence and mortality of hepatic carcinoma (HCC) remain high, and early diagnosis of HCC is seen as a key approach in improving clinical outcomes. However, the sensitivity and specificity of current early screening methods for HCC are not satisfactory. In recent years, research around exosomal miRNA has gradually increased, and these molecules have emerged as attractive candidates for early diagnosis and treatment of HCC. This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.

Keywords: Hepatic carcinoma; Early diagnosis; Exosomal miRNA; Biomarker

Core Tip: The prognosis of hepatic carcinoma (HCC) is poor and surgical resection is the only potential radical cure. Early diagnosis of HCC is a key approach in improving clinical outcomes. However, the sensitivity and specificity of current early screening methods for HCC are not satisfactory. Exosomal miRNAs have become a candidate for early diagnosis and treatment of HCC. This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.